CMV Viremia
13
4
4
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
1 terminated out of 13 trials
75.0%
-11.5% vs benchmark
8%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
Expansion of Virus-Specific Lymphocytes for Cell Therapy
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients
CMV Infection and Immune Intervention After Transplantation
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease